O'Melveny
We only have limited information for this firm. Consider the following firms which have provided more information:
Combining a ‘deep understanding and insight into Chinese culture, laws and regulations and business norms’ with an ’advanced familiarity of Western practices’, O'Melveny is a popular choice among Chinese issuers and banks across a range of ECM matters, including IPOs, global offerings and follow-on issuances. Under the guidance of Edwin Kwok and Ke Zhu, the firm has gained most prominence as a result of its ability to provide ‘feasible and effective solutions’ in the context of biotech and life sciences issuances.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'The lawyers are very professional, efficient and dedicated, and they are able to answer our concerns and questions in a timely manner to facilitate the development of the project.'
- 'They have a deep understanding and a unique insight into Chinese culture, laws and regulations and business norms which they combine with an advanced familiarity of Western practices.'
Abbreviated data is displayed for this firm.
Key clients
- Luzhu Biotech
- Beauty Farm
Abbreviated data is displayed for this firm.
Work highlights
- Advised Luzhu Biotech on its Hong Kong IPO.
- Advised Beauty Farm on its Hong Kong IPO.
Abbreviated data is displayed for this firm.